Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) FCF Margin (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed FCF Margin for 7 consecutive years, with 587.13% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin fell 15397.0% to 587.13% in Q4 2025 year-over-year; TTM through Nov 2025 was 301.34%, a 3205.0% increase, with the full-year FY2025 number at 313.73%, up 1966.0% from a year prior.
  • FCF Margin was 587.13% for Q4 2025 at Nurix Therapeutics, down from 470.12% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 210.26% in Q4 2023 to a low of 587.13% in Q4 2025.
  • A 5-year average of 307.53% and a median of 355.54% in 2024 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: tumbled -127864bps in 2021, then skyrocketed 64737bps in 2023.
  • Nurix Therapeutics' FCF Margin stood at 429.6% in 2021, then decreased by -2bps to 437.11% in 2022, then surged by 148bps to 210.26% in 2023, then crashed by -306bps to 433.16% in 2024, then crashed by -36bps to 587.13% in 2025.
  • Per Business Quant, the three most recent readings for NRIX's FCF Margin are 587.13% (Q4 2025), 470.12% (Q3 2025), and 149.44% (Q2 2025).